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Malaria vaccine development has largely focused on Plasmodium falciparum; however, 
a reawakening to the importance of Plasmodium vivax has spurred efforts to develop 
vaccines against this difficult to treat and at times severe form of relapsing malaria, 
which constitutes a significant proportion of human malaria cases worldwide. The almost 
complete dependence of P. vivax red blood cell invasion on the interaction of the P. vivax 
Duffy-binding protein region II (PvDBP_RII) with the human Duffy antigen receptor for 
chemokines (DARC) makes this antigen an attractive vaccine candidate against blood-
stage P. vivax. Here, we generated both preclinical and clinically compatible adenoviral 
and poxviral vectored vaccine candidates expressing the Salvador I allele of PvDBP_RII – 
including human adenovirus serotype 5 (HAdV5), chimpanzee adenovirus serotype 63 
(ChAd63), and modified vaccinia virus Ankara (MVA) vectors. We report on the antibody 
and T cell immunogenicity of these vaccines in mice or rabbits, either used alone in a 
viral vectored prime-boost regime or in “mixed-modality” adenovirus prime – protein-
in- adjuvant boost regimes (using a recombinant PvDBP_RII protein antigen formulated 
in Montanide®ISA720 or Abisco®100 adjuvants). Antibodies induced by these regimes 
were found to bind to native parasite antigen from P. vivax infected Thai patients and 
were capable of inhibiting the binding of PvDBP_RII to its receptor DARC using an in vitro 
binding inhibition assay. In recent years, recombinant ChAd63 and MVA vectors have been 
quickly translated into human clinical trials for numerous antigens from P. falciparum as 
well as a growing number of other pathogens. The vectors reported here are immunogenic 
in small animals, elicit antibodies against PvDBP_RII, and have recently entered clinical 
trials, which will provide the first assessment of the safety and immunogenicity of the 
PvDBP_RII antigen in humans.
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introduction
Malaria is caused by protozoan parasites of the genus Plasmodium, 
with five species known to infect humans. Despite extensive efforts 
with existing control measures, the levels of morbidity and mor-
tality associated with this disease remain sobering. Historically, 
vaccine development efforts have almost exclusively focused on 
Plasmodium falciparum – the major causative agent of malarial 
disease in sub-Saharan Africa (1). A second species of parasite, 
Plasmodium vivax, is the most widespread geographically and 
thus constitutes a significant proportion of human malaria cases 
worldwide. Although viewed for many decades as a relatively 
inconsequential parasite (2), revised estimates suggest 2.5 billion 
people are living at risk of P. vivax infection in the Americas, as well 
as Central and South-East Asia (3). Recent data also demonstrate 
that the infection brings a significant burden of morbidity and 
associated mortality, which has been largely under-appreciated in 
the past (4). Consequently, the recently revised Malaria Vaccine 
Technology Roadmap to 2030 (5) now recognizes the importance of 
P. vivax malaria and calls for a vaccine to achieve 75% efficacy over 
2 years – equally weighted with P. falciparum in an era of renewed 
political will to control and eradicate this devastating disease.
Different stages of the malaria parasite’s life-cycle can be 
targeted by subunit immunization. In the past, a small handful 
of pre-erythrocytic and sexual-stage vaccine candidates for P. 
vivax, based on the PvCSP and Pvs25 antigens respectively, have 
entered early phase clinical testing as recombinant protein or long 
synthetic peptide in adjuvant formulations (6–9); none of these 
candidate formulations, however, remain in active clinical trials. 
Vaccines targeting the asexual blood-stage infection remain an 
alternative approach, aiming to control and clear parasitemia in 
order to prevent disease and death as well as continued transmis-
sion. A number of blood-stage malaria vaccine candidates, mainly 
focusing on merozoite ligands involved in erythrocyte invasion, 
are under development for P. falciparum (10) but, as yet, no clinical 
trials of equivalent P. vivax blood-stage candidate vaccines have 
been reported (11).
Merozoite invasion of erythrocytes is a complex, multi-step 
process involving many receptor–ligand interactions between 
the parasite and the surface of the host’s red blood cell (RBC) 
(12). Invasion of RBCs by P. vixax is restricted to CD71+ reticu-
locytes (13) and commonly uses the interaction of the P. vivax 
Duffy-binding protein (PvDBP) with the human Duffy antigen 
receptor for chemokines (DARC/Fy) (14). Notably, Duffy-negative 
individuals appear to be protected from blood-stage P. vivax 
infection, an observation first reported by Miller et al. in 1976 
(15), confirmed by controlled human infection studies (16), and 
associated geographically with sub-Saharan Africa where P. vivax 
is largely absent (17). Of note, there have been reports of P. vivax 
isolates that can invade Duffy-negative cells (18), with recent 
sequencing data identifying a gene encoding a PvDBP paralog 
(19). These data suggest that increased expression levels or gene 
copy number may enable invasion into Duffy-negative cells, and 
further highlight the importance of the PvDBP antigen in P. vivax 
infection.
The micronemal parasite ligands (DBPs or erythrocyte-binding 
ligands/antigens, EBL/EBA) are a family of antigens that are 
functionally conserved across Plasmodium species. All parasites 
have at least one EBL, and in many cases these lead to redundancy, 
as observed in P. falciparum (20). In the case of P. vivax, the 
PvDBP gene and its paralog are known to exist (19), and genetic 
knockout of the orthologous simian malaria P. knowlesi DBPα 
gene prevents invasion of Duffy-positive erythrocytes in vitro (21). 
The receptor-binding domain of PvDBP lies within the conserved, 
extracellular, cysteine-rich region known as region II (PvDBP_RII) 
(22). Antibodies can be induced against this antigen in mice and 
rhesus macaques using recombinant PvDBP_RII protein (rDBP)-
in-adjuvant vaccines (23, 24), and those raised against the P. 
knowlesi DBPα ortholog can block RBC invasion by this parasite 
in vitro (25). Furthermore, naturally acquired high-titer binding 
inhibitory antibodies against PvDBP_RII have been shown to 
be associated with reduced risk of P. vivax infection in children 
residing in an endemic area, as well as lower P. vivax parasite 
densities following infection (26). Thus, to date, the PvDBP_RII 
adhesin remains the most promising subunit vaccine target 
against P. vivax merozoites; however, this antigen has never been 
progressed to clinical trials and, consequently, no data have existed 
on the ability of vaccines to induce effective immune responses in 
humans.
Traditionally, recombinant protein vaccines have been developed 
when seeking to induce antibodies by vaccination. Development of 
such vaccines requires production of the antigen in a heterologous 
expression system followed by formulation in a suitable human-
compatible adjuvant (27). An alternative approach, developed 
in recent years, has used recombinant viral vectored vaccines to 
deliver proteins of interest with the key aim of inducing antibodies 
in conjunction with T cell responses. A strategy demonstrating 
the highest degree of success to date has utilized a recombinant 
replication-deficient adenovirus to prime an immune response, 
followed by a booster vaccination (typically 8 weeks later) with an 
attenuated poxvirus recombinant for the same antigen (28). This 
approach has been shown to be reliably immunogenic for high-
titer antibody induction against a variety of difficult-to-express 
malaria antigens in mice, rabbits, and non-human primates (NHP) 
(29–32). It has also been shown to be safe and immunogenic for the 
delivery of the P. falciparum blood-stage antigens merozoite surface 
protein 1 (PfMSP1) and apical membrane antigen 1 (PfAMA1) in 
a series of Phase I/IIa clinical trials in healthy adult UK volunteers 
(33), and the same viral vectored vaccine technologies are currently 
entering Phase II/III clinical testing in West Africa for Ebola (34).
An extension of this approach has seen the development of 
“mixed modality” adenoviral prime – protein-in-adjuvant boost 
(AP) regimes, whereby the two leading subunit vaccine delivery 
platforms are combined, often leading to improved immune 
responses in mice in comparison to the use of either strategy alone 
(35, 36). In agreement with these murine data, NHP studies of 
similar regimes, for candidate malaria and HIV-1 vaccines, have 
also shown particular promise (30, 37, 38). Here, we generated 
both preclinical and clinically compatible adenoviral and poxviral 
vectored vaccine candidates expressing PvDBP_RII. We report on 
the humoral and cellular immunogenicity of these vaccines in mice 
or rabbits, either used alone in a viral vectored prime-boost regime 
or in AP regimes using a recombinant protein PvDBP_RII antigen 
administered in adjuvant. Antibodies induced by these regimes 
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were found to bind to native parasite antigen from P. vivax infected 
patients and were capable of inhibiting the binding of PvDBP_RII 
to its receptor DARC in vitro.
Materials and Methods
Vaccines and Protein
Viral vectored vaccines expressing PvDBP_RII were generated 
according to previously described methods. Recombinant viruses 
each express the 984  bp coding sequence of region II of the 
Duffy-binding protein from the Salvador I (SalI) strain of P. vivax, 
amino acids (αα) 194–521 (GenBank Accession #DQ156512). The 
PvDBP_RII construct was codon optimized for human expres-
sion and synthesized by GeneArt (Regensburg, Germany). The 
PvDBP_RII sequence was cloned in frame at the N-terminus to 
the human tissue plasminogen activator (tPA) leader sequence 
(αα 1–32, GenBank Accession # K03021), which in turn was 
preceded by a Kozak sequence (29). This transgene cassette was 
inserted using Gateway® site specific recombination technology 
(Invitrogen) into the E1 site of vectors encoding the genomes of 
E1/E3-deleted HAdV5 (29) and ChAd63 (39), under the control 
of the 1.9 kbp CMV promoter (40). The entire E4 locus of the 
ChAd63 vector is also replaced with the E4Orf6 gene from HAdV5 
as previously described (39). The recombinant adenoviral vaccines 
were generated and cultured in HEK293 cells, purified by CsCl 
centrifugation, and titered by UV spectrophotometry to give units 
of viral particles (vp/mL) (41) or by anti-hexon immunostain-
ing of infected T-REx-293 cells to give infectious units (ifu/mL) 
(31). In the case of modified vaccinia virus Ankara (MVA), the 
transgene cassette was recombined into the thymidine kinase 
(TK) locus of MVA with expression driven by the vaccinia P7.5 
early/late promoter. Recombinant MVA viruses were generated as 
previously described – either with an additional GFP marker gene 
(29) or without any additional marker (35). Both MVA vaccines 
were grown in chicken embryo fibroblasts (CEFs), purified by 
centrifugation through a sucrose cushion, and titered by plaque 
assay to give plaque-forming units (pfu/mL) (41). Control vectors 
expressing ovalbumin (OVA) have been described previously (36).
Unless otherwise stated, all studies used rDBP produced 
in Escherichia coli and purified as previously described (42). 
Endotoxin levels were measured using the Limulus amebocyte 
lysate (LAL) gel-clot assay according to the manufacturer’s instruc-
tions (Salesworth). The endotoxin content was <22 EU per 25 μg 
protein.
For the rabbit serum ELISAs, rDBP was produced in suspension 
HEK293E cells. The construct included from N- to C-terminus: 
the human tPA leader sequence and PvDBP_RII (as for the viral 
vector vaccines), followed by an AviTag biotin acceptor peptide 
(amino acids GLNDIFEAQKIEWHE) followed by a hexa-histidine 
(His6) tag. Six liters of suspension HEK293E cells were transiently 
transfected as previously described (32), and culture supernatants 
were harvested after 4 days when cell viability fell below 95%. This 
was then concentrated 20-fold and subsequently buffer exchanged 
into PBS using a Pellicon 3 tangential flow filtration (TFF) system 
(Millipore, Herts, UK). Purification consisted of a cobalt-based 
immobilized metal affinity chromatography (IMAC) – Hitrap 
TALON crude (GE Healthcare, Bucks, UK) and a size exclusion 
chromatography (SEC) – SepFast GF-HS-L 16/1000 (Biotoolomics, 
Durham, UK). The purified protein was quantified by Nanodrop 
(Thermo Fisher Scientific, Leics, UK) and stored at −80°C until 
further use.
Vaccine adjuvants
Adjuvants used in this study were dosed and prepared in low 
phosphate PBS (<5mM) (Gibco-Invitrogen, UK) as previously 
described (36). In brief, Abisco®100 (Isconova, Sweden) (12 μg/
dose) was gently mixed with antigen in PBS; and Montanide®ISA720 
(Seppic, France) was emulsified using a T10 ULTRA-TURRAX® 
(IKA®) homogenizer under sterile conditions at 25,000 rpm for 
6 min, keeping the sample on ice in a ratio of 3:7 (antigen:adjuvant). 
All vaccines were kept on ice until administration. Abisco®100 is 
an ISCOMatrix containing phosphatidyl choline phospholipid, 
cholesterol, and saponins purified from the tree Quillaja saponaria 
Molina – a mixture of Matrix A and Matrix C (containing the QS7 
and QS21 fractions respectively) purified from the Quil-A extract. 
Montanide®ISA720, an oil-in-water emulsion, is produced with 
squalene oil and a refined surfactant based on mannide oleate.
animals and immunizations
All procedures on mice were performed in accordance with the 
terms of the UK Animals (Scientific Procedures) Act Project 
License and were approved by the University of Oxford Animal 
Welfare and Ethical Review Body. Six to eight-week-old female 
BALB/c (H-2d) mice were purchased from Harlan Laboratories 
(Oxfordshire, UK) or bred at the Wellcome Trust Centre for 
Human Genetics (Oxford, UK). Mice were anesthetized before 
immunization with Isoflo (Abbot Animal Health, UK), and all 
immunizations were administered intramuscularly (i.m.) with 
vaccine divided equally into each musculus tibialis. Immunization 
doses and regimes are explained in the text and figure legends. 
Serum was harvested at stated time-points from tail vein bleeds or 
by exsanguination under terminal anesthesia at the final harvest 
time-point.
Rabbit work was conducted by Biogenes (Germany). Female 
ZiKa rabbits (n = 4) were immunized i.m. with 4 × 108 ifu HAdV5-
PvDBP_RII on day 0 and 5 × 107 pfu MVA-PvDBP_RII (ML) on 
day 56. Two control rabbits received the same doses and regime 
of viral vectors encoding OVA (36). Serum was harvested before 
immunization (day 0) and 28, 56, and 70 days post adenovirus 
administration.
enzyme linked immunosorbent assay
Unless stated otherwise, mouse IgG ELISAs were carried out 
using a standardized ELISA according to previously described 
methodology (43, 44) and using a reference sample generated 
from high-titer sera pooled from PvDBP_RII vaccinated mice. 
A 1:9000 dilution of the reference sample gave an OD405 = 1.0, 
and thus this reference serum was taken to be 9000 arbitrary 
units (AU). Test samples were diluted appropriately so that their 
optical density 405 nm (OD405) could be read off the linear part 
of the reference curve. Alternatively, and where stated in the text, 
endpoint ELISAs were performed as described previously (29). 
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In brief, Nunc-Immuno Maxisorp plates (Thermo Scientific, UK) 
were coated overnight at room temperature (RT) with PvDBP_RII 
protein. Plates were washed with PBS/0.05% Tween 20 (PBS/T) 
and blocked for 1 h with 10% skimmed milk powder in PBS/T. 
Serum samples were diluted in PBS/T and added in duplicate, 
with threefold dilutions down the plate, before incubation for 
2 h at RT. After washing, goat anti-mouse total IgG conjugated 
to alkaline phosphatase (Sigma Aldrich, UK) was added for 1 h 
at RT, followed by a final wash, and then addition of 1 mg/mL 
p-nitrophenylphosphate in diethanolamine buffer (Pierce, UK) as 
developing substrate. OD405 was read using a Model 550 Microplate 
Reader (Bio-Rad, UK). Serum antibody endpoint titers were taken 
as the x-axis intercept of the dilution curve at an absorbance value 
3 SDs greater than the OD405 for naïve mouse serum. A standard 
positive serum sample and naïve serum sample were included as 
controls for each assay. The same methodology was used for rabbit 
endpoint ELISAs except that PvDBP_RII protein was produced 
in HEK293E cells and an anti-rabbit IgG secondary was used as 
described previously (45).
isotype elisa
To measure antigen-specific IgG1 and IgG2a responses, plates were 
coated as before but at a concentration of 1 μg/mL protein. After 
blocking, serum diluted 1:1000 in PBS/T was added in duplicate 
to the plate for 2 h at RT. Plates were then washed and either biotin 
anti-mouse IgG1 or IgG2a (BD biosciences) at a 1:5000 dilution 
were added to the test plates for 1 h at RT. Following washing and 
a 30 min incubation with Extravidin Alkaline Phosphatase (Sigma 
Aldrich, UK), plates were developed as for total IgG ELISA. A 
standard positive serum sample and naïve mouse serum sample 
were included as controls.
isolation of splenocytes
Splenocytes were prepared fresh from mouse spleens as previously 
described (46). Where stated in the text, samples were also frozen 
down in 1 mL aliquots fetal calf serum (FCS) with 10% DMSO 
and stored at −80°C. Prior to use, frozen samples were thawed and 
immediately added to pre-warmed media [minimal essential media 
(MEM) α-modification containing 4 mM l-glutamine, 100 U/mL 
penicillin, 100 μg/mL streptomycin, 50 μM β-mercaptoethanol, 
and 10% heat-inactivated FCS]. Cells were then washed twice 
with media and allowed to rest at 37°C, 5% CO2 in a humidified 
incubator for 1 h before use.
Ex Vivo iFn-γ spleen elispot
IFN-γ ELISpots were performed using splenocytes as previously 
described (36). In brief, spleen cells were re-suspended at 1 × 107 
cells/mL in complete medium and plated at 50 μL cells per well. 
Fifty microliters complete medium alone was added to control 
wells, and 50 μL re-stimulation in complete medium was added 
to duplicate test wells as follows: rDBP at a final concentration 
5 μg/mL; or a pool of 32 20mer peptides (NEO Peptide, USA) 
overlapping by 10 amino acids (except the final peptide, number 
32, was an 18mer) corresponding to the whole of the PvDBP_RII 
coding sequence at a final concentration 5 μg/mL each peptide; or 
individual peptides used at 5 μg/mL final concentration. Results 
are expressed as spot forming units (SFU) per million splenocytes. 
Background responses in media-only wells were subtracted from 
those measured in re-stimulated wells.
intracellular cytokine staining
Mouse splenocytes were restimulated for 5  h at 37°C in the 
presence of GolgiPlug (BD Biosciences) and peptides [single or 
overlapping peptides (OLP) pool] specific for PvDBP_RII at a final 
concentration of 1 μg/mL per peptide (or no peptide unstimulated 
control), before storage at 4°C overnight. Cells were then incubated 
for 15 min in the presence of anti-mouse CD16/CD32 (Fc-block) 
before surface staining for 30  min, with anti-mouse CD8α-
PerCP-Cy5.5 (clone 53-6.7) and CD4-Pacific Blue (clone GK1.5) 
and LIVE/DEAD Fixable Aqua Dead Cell Stain Kit for 405 nm 
excitation (Invitrogen). Permeabilization was performed using 
Cytofix/Cytoperm solution (BD Biosciences) according to the 
manufacturer’s instructions. Cells were stained intracellularly for 
30 min with anti-mouse IFN-γ-Alexa Fluor 647 (clone XMG1.2). 
All incubations were performed at 4°C with staining antibodies 
from eBioscience. Cells were resuspended in 1% formalin solution 
and analyzed using a LSRII flow cytometer (BD Biosciences). Data 
were analyzed using FlowJo version 9.7.5. Background responses 
from the unstimulated control cells were typically 0.05%.
Binding inhibition assay
A binding inhibition assay was carried out to study the ability of 
antibodies raised in mice against PvDBP_RII to inhibit the binding 
of this protein to its receptor DARC, as previously described (42, 
47). Sera diluted as indicated were pre-incubated with 0.025 μg/mL 
of recombinant PvDBP_RII (SalI strain sequence) for 1 h at RT 
before adding to ELISA plates pre-coated with recombinant DARC 
(nDARC-Fc; N-terminal extracellular 60 amino acids of DARC 
fused to Fc region of human IgG) protein at 1 μg/mL. Bound 
PvDBP_RII was detected with rabbit polyclonal anti-PvDBP_RII 
sera (1:4000 dilution), followed by goat anti-rabbit IgG HRP-
conjugated antibodies (1:6000 dilution). A standard curve gener-
ated using binding of PvDBP_RII (0.002–0.025 μg/mL) to DARC 
was used to convert OD values into amount of protein bound 
in each well. Percent inhibition was calculated as 100% minus 
% protein bound. A positive control serum (raised in mice against 
PvDBP_RII using Freund’s adjuvant) and a negative control serum 
(from naïve mice) were included in each assay. The negative control 
sample had a median of 4% binding inhibition across all replicates 
tested across the different dilutions.
indirect immunofluorescence assay
Plasmodium vivax-infected blood was collected from malaria 
patients attending the clinics of the Shoklo Malaria Research 
Unit (SMRU), Mae Sot region northwest of Thailand, after writ-
ten informed consent (OXTREC 027-025; University of Oxford, 
Centre for Clinical Vaccinology and Tropical Medicine, Oxford, 
UK). The P. vivax-infected erythrocytes were cultured to the late 
schizont stage prior to being concentrated and washed as previ-
ously described (48), before being smeared onto glass slides, air 
dried, and fixed with cold acetone for 20 min. For the immunofluo-
rescence assays (IFAs), the thin-smear preparations were blocked 
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with 1% Casein, 10% goat serum in PBS for 1 h at RT. Mouse sera 
(diluted 1:50) or rabbit sera (diluted 1:100) were applied to the 
slides and incubated for 1.5 h at 37.5°C or 1 h at RT in a humidified 
incubator, respectively. The slides were then washed three times 
with PBS before the addition of anti-mouse or anti-rabbit IgG 
conjugated to Alexa Fluor 488 (Molecular Probes) diluted 1:100 
(mouse) or 1:1000 (rabbit) with 1% Casein, 10% goat serum in 
PBS for 1  h at RT, and mounted with Vectashield (Vectorlabs) 
with DAPI (4′,6-diamidino-2-phenylindole) (Invitrogen). Binding 
was visualized using a Nikon TS 100 epifluorescence microscope.
statistical analysis
All statistical analysis was carried out using Prism version 5.04 
(Graphpad, USA). For non-parametric data, a Kruskal–Wallis test 
with Dunn’s multiple comparison post-test was used to compare 
more than two groups, and a Mann–Whitney U-test was used 
to compare two groups. A two-way ANOVA with Bonferroni’s 
multiple comparison post-test was used to explore the effect of 
two variables. P < 0.05 was considered significant.
results
antibody responses induced by  
adenovirus-MVa PvDBP_rii Vaccines
Viral vectored vaccines, when used in a heterologous prime-boost 
regime, have previously been shown in various preclinical animal 
models to induce functional antigen-specific antibody responses 
targeting P. falciparum antigens, such as PfMSP1, PfAMA1, 
PfRH5, and Pfs25 (30–32, 45, 49, 50). Here, we initially generated 
recombinant viral vectors for use in preclinical proof-of-concept 
studies: a human adenovirus serotype 5 (HAdV5) vector expressing 
PvDBP_RII, and a MVA expressing the same PvDBP_RII antigen, 
as well as a selectable marker (green fluorescent protein, GFP) 
under the control of separate promoters.
BALB/c mice were immunized with 1010 viral particles (vp) 
HAdV5-PvDBP_RII and boosted 8 weeks later with 107 plaque 
forming units (pfu) MVA-PvDBP_RII (GFP). Total IgG titers 
were assayed against rDBP by ELISA in serum 2 weeks after each 
immunization and before the boost. Antigen-specific antibody 
responses were detected 14  days post-HAdV5 immunization 
(Figure  1A). These responses continued to increase by day 55 
and were boosted by MVA vaccine administration on day 56. These 
responses confirmed the ability of viral vectored vaccines to induce 
anti-PvDBP_RII IgG.
Owing to high levels of pre-existing immunity to HAdV5 within 
the human population, other adenoviral vectors have been sought 
for clinical vaccine development (51). Simian adenoviruses, against 
which there is typically minimal neutralization by human sera, 
have emerged as a leading alternative (28, 52). In particular, the 
chimpanzee adenovirus serotype 63 (ChAd63) has been found to 
induce strong cellular and humoral immune responses, compara-
ble to HAdV5 in animal models, and has also been shown to be safe 
and highly immunogenic in clinical trials (44, 53, 54). Having dem-
onstrated the humoral immunogenicity of the preclinical HAdV5 
and MVA vectors, we next sought to do the same with clinically 
compatible vectors and undertook a comparative immunogenicity 
study. We thus generated a ChAd63 vector expressing PvDBP_RII, 
as well as a recombinant MVA-PvDBP_RII vector lacking the GFP 
marker gene (“markerless”, ML) before undertaking a comparative 
immunogenicity assessment. Adenoviral vectors may be titered 
by either assessing vp or infectious units (ifu). Unlike vp counts, 
the ifu titer only measures virus capable of infecting cells, and 
therefore dosing based on ifu provides the most appropriate means 
for comparing adenoviral vector immunogenicity (39).
BALB/c mice were thus immunized with 1.5 × 108 ifu HAdV5 
or ChAd63 encoding PvDBP_RII, and 8 weeks later were boosted 
with 107 pfu MVA-PvDBP_RII (GFP) or MVA-PvDBP_RII (ML). 
As before, total IgG titers were assayed in serum 2 weeks after each 
immunization and before the boost by ELISA against PvDBP_RII 
protein. Following immunization with ChAd63-PvDBP_RII, the 
IgG responses followed the same antibody kinetic as observed with 
HAdV5. Similarly, there was no significant difference between total 
IgG titers 14 days after the priming immunization with HAdV5 or 
ChAd63 (P = 0.09, Mann–Whitney test, n = 6 per group), although 
there was a trend toward lower antibody titers with ChAd63 
(Figure  1B). By day 55, this difference had become significant 
when IgG titers were compared between mice receiving HAdV5 
versus ChAd63 (P = 0.0002, Mann–Whitney test, n = 6 versus 
9); however, after the MVA boost immunization, there were no 
significant differences observed in the IgG titers at day 70 following 
the three different regimes tested (P = 0.11, Kruskal–Wallis test 
with Dunn’s multiple comparison post-test). These data showed the 
immunogenicity of the ChAd63 vector as well as the comparable 
immunogenicity of the markerless and GFP-expressing MVAs.
antibody responses induced by  
adenovirus-Protein PvDBP_rii Vaccines
We next assessed the ability of a “mixed modality” immunization 
approach (28) to maximize antibody induction by subunit vaccina-
tion. Adenovirus-protein/adjuvant (AP) and protein/adjuvant-only 
(PPP) regimes have previously been shown to induce higher titer 
antibody responses than the adenovirus-MVA regime (AM) in mice 
(35, 36), rhesus macaques (30), and humans (55). BALB/c mice were 
thus immunized with 1010 vp HAdV5-PvDBP_RII and boosted 
8 weeks later with 10 μg of PvDBP_RII protein (AP) formulated 
in two different adjuvants – Montanide®ISA720 and Abisco®100. 
Both adjuvants have previously been shown to induce high-titer 
responses in both AP and PPP regimes when tested with the model 
antigen OVA (36). For comparison, mice were also immunized 
three times, 21 days apart, with 10 μg PvDBP_RII protein (PPP) 
formulated in the same adjuvants, or with HAdV5-MVA (AM) as 
before. Total IgG titers were assayed in serum 2 weeks after the 
second protein immunization (PP) in the PPP groups, and after 
the final immunization in all groups by ELISA against PvDBP_RII 
protein (Figure  1C). Following three protein immunizations 
(PPP), there were no differences between the two adjuvants tested, 
although after two protein vaccinations (PP) Abisco®100 performed 
slightly better than Montanide®ISA720. Moreover, similar to previ-
ous studies using other antigens, median anti-PvDBP_RII IgG titers 
were over 10-fold higher in mice immunized with the AP and PPP 
regimes in comparison to those immunized with the AM regime 
[reaching significance for PPP (Abisco®100) versus AM following 
Kruskal–Wallis test with Dunn’s multiple comparison post-test, 
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P <  0.01]. Overall, these data confirmed that the highest titer 
IgG responses against PvDBP_RII in mice can be achieved in the 
context of either PPP or AP immunization regimes in conjunction 
with relatively “strong” adjuvants.
igg isotype responses induced by  
PvDBP_rii Vaccination
To further characterize the vaccine-induced antibody responses 
against PvDBP_RII, serum IgG1 and IgG2a isotype responses 
were assessed by ELISA 2  weeks after the final vaccination in 
mice immunized with the AP, PPP, and AM regimes outlined 
previously. Both antibody subclasses were induced by each regime 
tested (Figure 2A); however, as previously reported (36), a more 
balanced isotype response was induced in the context of AP and 
AM immunization – most likely reflecting stronger polarization 
toward Th1-type IgG2a when using a viral vector. A similar 
effect was observed for the Abisco®100 adjuvant in the context 
FigUre 1 | humoral responses induced by viral vectored and protein 
vaccines targeting PvDBP_rii. (a) BALB/c mice (n = 5) were immunized 
with 1010 vp of a recombinant HAdV5 expressing PvDBP_RII, and boosted 
8 weeks later with 107 pfu of a recombinant MVA expressing PvDBP_RII and 
the selectable marker GFP. (B) BALB/c mice (n = 6/group) were immunized 
with 1.5 × 108 ifu of either HAdV5 or ChAd63 expressing PvDBP_RII, and 
8 weeks later, mice were boosted with 107 pfu MVA-PvDBP_RII either 
expressing the selectable marker GFP or no marker (ML). (c) BALB/c mice 
(n = 4–6/group) were immunized with the regime outlined in (a) (AM), or 
immunized three times i.m. 3 weeks apart with 10 μg of PvDBP_RII protein 
formulated with the specified adjuvant (PPP), or primed i.m. with 1010 vp of 
HAdV5-PvDBP_RII and boosted 8 weeks later i.m. with 10 μg of PvDBP_RII 
protein formulated with adjuvant (AP). In all panels, serum IgG titers were 
measured in arbitrary units (AU) against PvDBP_RII protein by ELISA 2 weeks 
after each immunization (day 14 and 70) and before the boost (day 55) in (a,B), 
and 2 weeks after the second immunization (PP) or final immunization (PPP, AP, 
AM) in (c). In (c), responses following two immunizations are shown with open 
symbols (PP, AP, AM) and after three immunizations with closed symbols (PPP). 
ND, not done. Median and individual data points are shown. The dotted line 
indicates the threshold for responses above background in (B) determined 
using serum taken from the mice prior to any immunization. The same cut-off 
would apply in (a) but is not indicated.
of PPP immunization, in comparison to protein formulation in 
Montanide®ISA720 which resulted in a dominant Th2-type IgG1 
response. Analysis of the log isotype IgG1:IgG2a ratio showed a 
significant effect of immunization regime (AP versus PPP), consist-
ent with previously published data using other antigens (36), and 
conferring greater induction of IgG2a following a viral vectored 
priming vaccination (P = 0.005, two way-ANOVA) (Figure 2B). 
The effect of adjuvant was also significant (P = 0.009), driven by 
Abisco®100, which induced comparable levels of IgG2a in the 
context of both the AP and PPP regimes.
T cell immunogenicity of PvDBP_rii Vaccines
The induction of CD4+ T cell responses is also an important 
consideration in the context of antibody-inducing vaccination. 
Such responses are necessary to help B cell responses, and drive 
class-switching and somatic hypermutation within the germinal 
centers (56). We therefore undertook an assessment of the ability 
FigUre 2 | igg isotype responses induced by PvDBP_rii vaccination. 
BALB/c mice (n = 4–6/group) were immunized with the AM, AP, or PPP 
regimes as described in Figure 1c. IgG1 and IgG2a antibody responses 
were measured in the serum 2 weeks after the last immunization by ELISA 
against PvDBP_RII protein. (a) Individual and median responses are shown. 
The dotted line indicates the threshold for responses above background 
determined using serum taken from the mice prior to any immunization. 
(B) IgG1:IgG2a ratios were calculated and log transformed for the AP and 
PPP groups. Individual and median responses are shown.
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of the different immunization regimes to induce PvDBP_RII-
specific T cell responses. Initially, responses were assessed using 
an ex vivo IFN-γ ELISpot assay. Spleens were harvested from 
mice previously immunized with the AP and PPP PvDBP_RII 
regimes, during the resting memory phase (10 weeks after the final 
immunization). Splenocytes were re-stimulated for 18 h with rDBP 
and IFN-γ secretion assessed (Figure 3A). At this late memory 
time-point, moderate-to-low T cell responses were observed with 
a comparable magnitude irrespective of immunization regime or 
adjuvant. Median responses of 328 and 199 SFU/million spleno-
cytes were induced by PPP immunization using Abisco®100 and 
Montanide®ISA720, respectively, while the AP regimes using the 
same adjuvants showed median responses of 184 and 297 SFU/
million splenocytes.
In contrast to the observations here, previous studies with 
other antigens have generally shown stronger cellular responses 
when using viral vectored delivery platforms in comparison to 
protein-in-adjuvant (35, 36). The previous assay had also used 
recombinant protein for the re-stimulation phase, and not OLP 
which are most commonly used for such T cell assays. Protein 
antigen cannot bind directly to MHC molecules displayed on the 
surface of antigen presenting cells (APCs), and instead is most 
likely processed into peptides by the exogenous pathway before 
these are loaded onto MHC class II molecules. Re-stimulation 
with recombinant protein is thus unlikely to measure CD8+ T 
cell responses which require peptide presentation on MHC class 
I molecules. We therefore next sought to compare this assay to 
one using OLP, spanning the whole of the PvDBP_RII antigen. 
To maximize cellular responses, mice were immunized with 
the HAdV5–MVA regime, and spleens were harvested from 
mice 2  weeks after the MVA immunization. Splenocytes were 
subsequently re-stimulated with either OLP or rDBP in the 
ex vivo IFN-γ ELIspot assay (Figure 3B). A median response of 
244 and 254 SFU/million splenocytes was observed with OLP 
and rDBP, respectively (P = 0.59, Mann–Whitney U-test). These 
data suggest that the two stimuli perform comparably, perhaps 
indicating minimal CD8+ T cell induction against this antigen in 
BALB/c mice. Given we previously compared antigen-specific IgG 
immunogenicity from the different adenoviral and MVA vaccines, 
we also assessed the cellular immunogenicity across the different 
regimes previously tested in Figure  1B. As with the humoral 
immunogenicity, no significant differences were observed between 
the groups receiving an HAdV5 versus ChAd63 prime, or the GFP 
marker versus “markerless” MVA boost (P = 0.63, Kruskal–Wallis 
test) (Figure 3C).
To further characterize the T cell response to PvDBP_RII, 
the OLP were used to map H-2d T cell epitopes in these BALB/c 
mice. Each of the 32 individual peptides in the OLP pool were 
tested individually, and three peptides (7, 8, and 14) induced 
responses consistently above background in the tested spleen 
samples (Table 1 and Figure 3D). Responses were consistently 
strongest for peptide 14, accounting for most of the total response 
observed with the OLP pool. Responses against each of the three 
individual peptides were subsequently assessed in fresh spleen 
samples from HAdV5–MVA PvDBP_RII immunized mice using 
intracellular cytokine staining (ICS) and flow cytometric analysis. 
These results indicate that each of the three peptides re-stimulated 
CD4+ T cells (Figure 3E and Table 1) with no responses detected 
above background for CD8+ T cells (data not shown), in agreement 
with the earlier data that suggested a paucity of detectable CD8+ T 
cells responses against this antigen in BALB/c mice.
Vaccine-induced antibodies inhibit the  
PvDBP_rii-Darc interaction
The rationale behind a PvDBP_RII-based vaccine relies on the 
induction of high-titer antibodies that inhibit RBC invasion by 
preventing the interaction between PvDBP and its natural ligand, 
the Fy antigen/DARC. In the absence of an easily available and 
standardized P. vivax assay of growth inhibition activity to assess 
anti-merozoite antibody function in  vitro, a variety of in  vitro 
receptor–ligand binding inhibition assays have been developed 
(47, 57, 58). Here, we used a version of this assay to assess the ability 
of vaccine-induced antibodies to inhibit binding of rDBP to the 
recombinant N-terminus of DARC (47). Serum samples from mice 
immunized with the AM, PPP, and AP regimes described above 
(in Figure 1C) were assayed 2 weeks after the final immunization 
at day 70 (D70). Sera obtained from mice at day 55 (D55) after a 
priming immunization with HAdV5-PvDBP_RII (i.e., prior to a 
MVA or protein-in-adjuvant vaccine boost) were also tested. The 
binding inhibition of sera was tested at three different dilutions: 
1:1000, 1:2000, and 1:4000 (Figures 4A–C).
FigUre 3 | T cell responses induced by viral vectored and protein vaccines targeting PvDBP_rii.
(Continued)
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FigUre 3 | continued
(a) BALB/c mice (n = 4–5/group) were immunized with AP and PPP regimes 
against PvDBP_RII as described in Figure 1c. Ten weeks after the last 
immunization, spleens were harvested and T cell responses were measured 
from frozen spleen samples by ex vivo IFN-γ ELISpot following re-stimulation 
with 5 μg/mL recombinant PvDBP_RII protein (rDBP). Median and individual 
data points are shown. (B) BALB/c mice (n = 6) were immunized with 
HAdV5-PvDBP_RII and boosted 8 weeks later with MVA-PvDBP_RII using 
doses as in Figure 1B. Two weeks after the last immunization, splenic T cell 
responses were measured by ex vivo IFN-γ ELISpot following re-stimulation 
with 5 μg/mL rDBP or 2 μg/mL OLP. Median and individual responses are 
shown. (c) Splenic T cell responses were measured from frozen samples in 
the mice reported in Figure 1B 2 weeks after the boost immunization and 
using OLP. Median and individual responses are shown. (D) BALB/c mice 
were immunized with 1.5 × 108 ifu HAdV5-PvDBP_RII and 8 weeks later were 
boosted with 107 pfu MVA-PvDBP_RII (GFP). Splenic T cell responses were 
measured from frozen spleen samples harvested 2 weeks post-boost and 
following re-stimulation with 5 μg/mL individual peptides (1–32) or the OLP 
pool control. Results from a representative mouse are shown. (e) BALB/c 
mice were immunized with 1 × 108 ifu HAdV5-PvDBP_RII and 8 weeks later 
were boosted with 107 pfu MVA-PvDBP_RII. Spleens were harvested 15 days 
post-boost. Intracellular cytokine staining followed by flow cytometric analysis 
showed the IFN-γ responses induced to the OLP pool and the three 
strongest peptides (Table 1) were from CD4+ cells. Cells were gated on 
lymphocytes, and then (top row) singlets by forward scatter height (FSC-H) 
versus area (FSC-A), then live cells (dead cell marker versus side scatter area, 
SSC-A), and then CD4 versus CD8. Representative plots (bottom row) of 
IFN-γ versus SSC-A from CD4+ gated cells are shown from one mouse 
following no stimulation (Unstim) or re-stimulation with the OLP pool or 
peptide 14 (P14).
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High levels of binding inhibition, >90%, were achieved with 
sera from mice immunized with the AM regime when tested 
at 1:1000, and this effect was reduced following dilution of the 
serum (Figure 4A). Inhibition of binding was significantly greater 
when compared to that after a single HAdV5 immunization, in 
agreement with the increase in IgG titers following the MVA 
boost (Figure 1A). Binding inhibition observed in the AM group 
was largely comparable to that achieved by PPP immunization 
when using the Montanide®ISA720 adjuvant. Encouragingly, PPP 
immunization with the Abisco®100 adjuvant, or AP immunization 
using either adjuvant, showed similar high-level binding inhibition 
at 1:1000 serum dilution, which was better maintained at 1:4000 
dilutions.
Comparison across all regimes at the 1:4000 serum dilution 
confirmed low levels of binding inhibition (median 14.4%) in mice 
55  days after HAdV5-PvDBP_RII immunization (Figure  4D). 
Following a boost with MVA-PvDBP_RII (GFP), binding inhibi-
tion titers were significantly increased (median 62.7%) (P = 0.003, 
Mann–Whitney test). In comparison to the PPP and AP regimes, 
titers achieved by the AM viral vectors were not significantly 
different to Montanide®ISA720 immunized mice (median 65.0% 
for PPP and 78.0% for AP). However, PPP and AP immunization 
using Abisco®100 showed a significant improvement over the 
AM regime (medians of 88.0 and 86.0%, respectively) (P < 0.05, 
Kruskal–Wallis test). There was also a strong sigmoidal relation-
ship between binding inhibition and antigen-specific IgG titer, 
as measured by ELISA, across all tested samples and dilutions 
(Figure 4E), similar to other in vitro antibody assays measuring the 
functional activity of anti-merozoite antibodies (55, 59). Overall, 
these data indicated that the highest titers of binding inhibitory 
antibodies could be achieved in mice using an AP immunization 
regime or a PPP regime when formulating the protein vaccine in 
Abisco®100.
recognition of native Parasite antigen by 
Vaccine-induced antibodies
The in vitro binding inhibition assay utilizes rDBP, and does not 
confirm that vaccine-induced antibodies are capable of recognition 
of native antigen within the P. vivax parasite. In order to assess 
this, indirect IFAs were performed using slides prepared from 
the blood of P. vivax infected Thai patients. Slides were probed 
with serum taken 2 weeks after the final vaccination from mice 
immunized with the ChAd63-PvDBP_RII and MVA-PvDBP_RII 
(ML) vectors (AM regime) outlined above in Figure 1B. All of the 
sera tested from PvDBP_RII immunized mice were positive by IFA 
with a punctate staining pattern, suggesting binding of antibody 
to PvDBP antigen within the micronemes of daughter merozoites 
(Figure 5A). We also immunized rabbits with the HAdV5 and 
MVA vectors expressing PvDBP_RII. These rabbit sera recognized 
PvDBP_RII antigen by ELISA, with responses after the priming 
immunization showing a different kinetic to mice (Figure 5B), 
but similar to that seen in rabbits in previous studies with the AM 
regime (45, 49). Serum from these rabbits, but not from vector 
immunized controls, also recognized P. vivax schizonts with a 
punctate staining pattern (Figure 5C).
Discussion
It is almost 40 years since the first report that identified the Duffy 
blood group antigen as a critical determinant of susceptibility to 
P. vivax malaria (15). However, despite great strides in our under-
standing about the nature of the interaction between the PvDBP 
and its receptor, it has proved challenging to translate vaccine can-
didates based on this paradigm into early phase proof-of-concept 
clinical testing. As for many malaria vaccine candidates, this can be 
due to difficulties with scale-up and manufacture of clinical-grade 
protein antigen, access to effective adjuvants or delivery formula-
tions suitable for human use, as well as finite resources (2, 27). More 
recently, advances in subunit vaccine delivery platforms have made 
it relatively easier to raise strong immune responses against target 
antigens of interest in humans. One leading approach has seen the 
development of recombinant viral vectored technologies that allow 
for in situ expression of the encoded antigen from virally infected 
TaBle 1 | h-2d T cell epitopes mapped in PvDBP_rii.
Peptide number sequence
7 VNNTDTNFHRDITFRKLYLK
8 DITFRKLYLKRKLIYDAAVE
14 YSKVVENNLRSIFGTDEKAQ
32 OLP (20mers overlapping by 10 amino acids, except the final peptide 32 which is 
an 18mer) were used to map T cell epitopes in BALB/c mice following HAdV5-MVA-
PvDBP_RII immunization. Responses against the three peptides in the table were 
consistently observed by ex vivo IFN-γ ELISpot – results from a representative mouse 
are shown in Figure 3D. All three peptides were tested by ICS, and IFN-γ responses 
were observed from CD4+ T cells following flow cytometry (Figure 3E).
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cells, leading to the concomitant induction of strong cellular and 
humoral immunity (28, 51, 54). Notably, recombinant adenovirus 
and poxvirus vectors are now in clinical trials ranging from Phase 
I–III, as vaccine candidates against numerous pathogens including 
P. falciparum malaria (33, 60), HIV-1 (61), hepatitis C virus (62), 
Mycobacterium tuberculosis (63), influenza virus (64), and Ebola 
(34). In this study, viral vectored vaccines, based on both human 
and chimpanzee adenovirus serotypes as well as the poxvirus 
MVA, were generated and then assessed for their ability to raise 
cellular and humoral immune responses against the blood-stage 
P. vivax antigen PvDBP_RII in mice and rabbits. Moreover, 
immune responses elicited by viral vectored vaccines encoding 
PvDBP_RII were compared with responses elicited by immuniza-
tion with rDBP formulated with strong experimental adjuvants 
that have been used in human clinical trials (65, 66).
These studies confirmed that PvDBP_RII is immunogenic 
and elicits strong antibody responses when delivered either by 
adenoviral and MVA vectors or as recombinant protein formulated 
with adjuvant. Anti-PvDBP_RII-specific IgG antibody responses 
were induced by viral vectored vaccines, and these followed a 
similar kinetic to that previously observed in mice and rabbits in 
the context of a standard heterologous prime-boost (AM) regime 
with other candidate antigens (29, 36, 45, 49, 50). Consistent with 
studies using other malaria transgenes (45, 49, 50), there was no 
significant difference between IgG titers 2 weeks after a priming 
immunization with either HAdV5 or ChAd63, although there was 
a trend toward weaker antibody titers with ChAd63. Following 
a boost with recombinant MVA, and consistent with numerous 
other studies (45, 49, 67, 68), anti-PvDBP_RII titers and IFN-γ T 
cell responses were comparable irrespective of priming adenovirus 
vector, or use of a GFP marker gene in the recombinant MVA. 
In recent years, ChAd63 and markerless MVA vectors encoding 
target antigens from P. falciparum have been routinely progressed 
to Phase I/II clinical trials (44, 53, 69, 70), and the data here sug-
gest the vectors for PvDBP_RII are equally suitable for clinical 
development.
FigUre 4 | inhibition of PvDBP_rii binding to its receptor by vaccine-
induced antibodies. BALB/c mice (n = 4–5/group) were immunized with the 
AM, AP, and PPP regimes as described in Figure 1c. Binding inhibition assays 
were carried out as described in Section “Materials and Methods” using serum 
from the stated time-points at dilutions of 1:1000, 1:2000, and 1:4000. Each 
sample was run in duplicate or triplicate and the mean% binding inhibition 
calculated. The mean and SD of the% binding inhibition for the (a) AM,  
(B) PPP, and (c) AP groups are shown. The controls (n = 3) were high-titer 
mouse anti-PvDBP_RII serum samples. (D) Median and individual data points 
are shown for the 1:4000 serum dilution reported in (a–c). Data for day 55 
(D55) after HAdV5 are also included. *P < 0.05 and **P < 0.01, see Results for 
statistical tests. (e) Relationship between% binding inhibition and log10 
anti-PvDBP_RII IgG titer assessed by endpoint ELISA. Individual data points 
and non-linear regression curve are shown (n = 87).
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FigUre 5 | indirect iFa using serum from adenovirus-MVa PvDBP_
rii immunized mice and rabbits. (a) Indirect IFA using sera from 
PvDBP_RII and OVA control immunized mice (green) and microscope 
slides containing fixed P. vivax-infected cells obtained from patients in 
Thailand. Representative images are shown for both sets of sera. Nuclei 
were stained with DAPI. The merge plus bright field are also shown.  
(B) ZiKa rabbits (n = 4) were immunized with HAdV5-PvDBP_RII on day 0 
and MVA-PvDBP_RII on day 56. Serum was harvested before immunization 
(day 0) and 28, 56, and 70 days post-adenovirus administration. Serum 
IgG titers were determined by endpoint ELISA. Individual responses are 
shown and the solid line indicates the mean. The dotted line indicates the 
cut-off for a positive response – samples tested at 1:100 dilution that did 
not show an OD405 nm reading above negative control sera are plotted 
below this line. Rabbits immunized with the same vectors encoding OVA 
showed no detectable responses in the same ELISA assay (not shown).  
(c) Indirect IFA as in (a) using sera from the PvDBP_RII and OVA 
immunized rabbits (green). Two representative images are shown for both 
sets of sera.
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Protection against blood-stage merozoites requires high 
concentration of functional antibody, capable of inhibiting the 
rapid RBC invasion process (32, 71). More recently, “mixed 
modality” adenoviral prime – protein-in-adjuvant boost regimes 
have been developed, and in a recent Phase Ia clinical trial with 
PfAMA1 antigen, were shown to induce higher antigen-specific 
IgG responses than the standard AM regime (55). Given the avail-
ability of a protein PvDBP_RII vaccine that is also being progressed 
to clinical development (72), we also explored the utility of the 
AP mixed-modality approach with this antigen and two “strong” 
adjuvants that have been in clinical testing (65, 66). At the doses 
tested, the AP regime, using both Montanide®ISA720 and the 
Abisco®100 adjuvants, significantly outperformed the AM regime. 
In comparison to protein-only regimes, the AP regime performed 
comparably to two protein immunizations (PP) with Abisco®100, 
but tended to improve upon Montanide®ISA720. Following three 
protein immunizations (PPP), all regimes performed comparably 
in terms of the total anti-PvDBP_RII IgG response. These regimes 
also elicited comparable levels of IFN-γ T cell responses as meas-
ured by ELISpot assay, and in the case of BALB/c mice, these 
appeared largely composed of a CD4+ T cell response directed 
against one dominant, and at least two sub-dominant, epitopes. 
Natural exposure to P. vivax (73), as well as immunization of rhesus 
macaques with PvDBP_RII protein in Montanide®ISA720 (24), 
also elicits antigen-specific T cell responses detectable by ELISpot. 
Their role in providing help to B cell responses and/or contribution 
to acquired immunity remains to be better defined.
Consistent with previous reports (35, 36), adenoviral priming also 
skewed the antibody response toward the Th1-type IgG2a cytophilic 
isotype, especially in the case of Montanide®ISA720. The potential 
role of the equivalent human isotypes IgG1 and IgG3 in natural 
immunity against P. vivax remains unclear, although these subclasses 
tend to dominate in the natural response to merozoite antigens for 
both P. vivax and P. falciparum (74, 75) and likely mediate effector 
functions via their Fc including interactions with immune cells 
(76–78) and complement (79). The ability to tailor the quality of the 
antibody response by using different vaccination regimes in humans 
may allow for this question to be better addressed in the future. In 
a similar vein, the ability of different protein vaccine adjuvants to 
affect the “quality” or fine-specificity of the vaccine-induced IgG 
has been reported in some cases (80), but not others (81), and will 
warrant further investigation in the context of clinical trials.
The ability of vaccine-induced antibodies to block binding 
of PvDBP_RII protein to its receptor DARC was assessed here 
using an in vitro ELISA-based binding inhibition assay against 
the vaccine homologous SalI allele. The highest levels of binding 
inhibition were achieved with sera from mice immunized using 
the AP and PPP regimes containing Abisco®100 at a dilution of 
1:4000, with comparable but slightly lower inhibition seen at the 
same dilution when using sera from mice immunized with the 
AM regime or protein in Montanide®ISA720. These levels were 
comparable, if not better, than those previously reported in similar 
mouse studies (42). Notably, binding inhibition also correlated 
with IgG titers, as previously reported for this assay using sera 
from immunized rhesus macaques (24).
The antibodies induced here in mice and rabbits by the AM 
regime were also capable of recognizing native P. vivax parasite 
antigen as assessed by IFA using freshly isolated parasites from Thai 
patients, consistent with other studies using viral vectors to deliver 
leading P. falciparum antigens in rabbits and humans (31, 44). It 
is encouraging that these antibodies can recognize native parasite 
isolates. Studies of naturally acquired immunity following P. vivax 
exposure have reported the induction of strain-specific immunity 
(82, 83), and numerous sequence polymorphisms have been found 
within the PvDBP_RII antigen with the majority localized to 
subdomain 2 (SD2) (84, 85). Other studies have suggested that 
the more highly conserved SD3 is also important for PvDBP_RII 
engagement with DARC and can elicit strain-transcending block-
ing inhibitory antibodies (86). Indeed, the development of naturally 
acquired cross-reactive anti-PvDBP_RII antibodies that recognize 
and block binding of diverse PvDBP_RII domains from P. vivax 
field isolates have been reported albeit at low frequency (26). 
This may be due to the limited exposure time of the PvDBP_RII 
micronemal ligand prior to binding the DARC receptor.
In contrast to epidemiological data, preclinical immunogenic-
ity studies with the SalI allele of PvDBP_RII have shown that 
this immunogen is capable of eliciting high-titer, cross-reactive 
binding-inhibitory antibodies in the ELISA-based assay (80, 
86) and inhibitory capacity using an ex vivo invasion assay (87). 
These data suggest that PvDBP_RII vaccination using either viral 
vectors or recombinant protein formulated with adjuvant could 
elicit antibodies that quantitatively and qualitatively differ from 
those induced by natural exposure. Whether this translates into 
the development of potent immune responses in humans that 
cross-react with diverse variants, and provide protection against P. 
vivax blood-stage infections, will be important future questions for 
clinical trials with first-generation vaccines based on PvDBP_RII.
Overall, these data confirm the immunogenicity of clinically 
relevant viral vectors in small animal models. The ChAd63 and 
MVA vectors encoding PvDBP_RII (SalI) have since progressed 
to Phase Ia clinical testing in healthy adults in Oxford, UK 
(Clinicaltrials.gov NCT01816113). Given the on-going develop-
ment of a PvDBP_RII protein-based vaccine toward clinical manu-
facture (72), it will also be possible to test mixed-modality regimes 
in Phase Ia trials in due course, as recently performed for the 
PfAMA1 antigen using ChAd63, MVA, and protein-in-adjuvant 
(55). The clinical data with ChAd63 and MVA will provide the 
first opportunity to assess the safety and immunogenicity of the 
PvDBP_RII antigen in humans, and enable detailed insight into 
the human vaccine-induced antibody response against this leading 
target antigen.
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